Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2025;31(Suppl):S182-S195. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837

View: 1231 Download: 134 Crossref: 1

Prospect of emerging treatments for hepatitis B virus functional cure

Rex Wan-Hin Hui, Lung-Yi Mak, James Fung, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2025;31(Suppl):S165-181. Published online November 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0855

View: 1551 Download: 306 Crossref: 4

Reply to Correspondence

Reply to correspondence on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Antonio Bertoletti, Anthony T Tan

Clin Mol Hepatol. 2025;31(1):e113-e116. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0867

View: 898 Download: 31

Correspondence

Correspondence to letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Gi-Ae Kim, Seung Won Choi, Young-Suk Lim

Clin Mol Hepatol. 2025;31(1):e108-e109. Published online August 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0619

View: 884 Download: 31

Correspondence to editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”

Shunda Du, Karin Wisskirchen, Ke Zhang, Ulrike Protzer

Clin Mol Hepatol. 2025;31(1):e44-e47. Published online October 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0781

View: 965 Download: 41 Crossref: 1

Letter to the Editor

Presence of liver fibrosis in chronic hepatitis B patients with varying serum hepatitis B virus DNA levels: Letter to the editor on “Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B”

Jian Wang, Shaoqiu Zhang, Chuanwu Zhu, Yuanwang Qiu, Chao Wu, Rui Huang

Clin Mol Hepatol. 2025;31(1):e27-e30. Published online August 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0602

View: 861 Download: 45 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”

Cho-Rong Lee, Sung-Gyoo Park

Clin Mol Hepatol. 2024;30(4):1053-1054. Published online July 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.0572

View: 1594 Download: 45 Web of Science: 1 Crossref: 1

Reply to correspondence on “Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients”

Beom Kyung Kim

Clin Mol Hepatol. 2024;30(4):1044-1046. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0584

View: 1090 Download: 25

Original Article

Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B

Gi-Ae Kim, Seung Won Choi, Seungbong Han, Young-Suk Lim

Clin Mol Hepatol. 2024;30(4):793-806. Published online July 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0252

View: 2623 Download: 199 Web of Science: 4 Crossref: 6

Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting

Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du

Clin Mol Hepatol. 2024;30(4):735-755. Published online May 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0058

View: 3422 Download: 332 Web of Science: 1 Crossref: 4

Editorial

Class II transactivator restricts viral replication, extending its effect to HBV: Editorial on “Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction”

Cho-Rong Lee, Sung-Gyoo Park

Clin Mol Hepatol. 2024;30(4):724-727. Published online July 3, 2024

DOI: https://doi.org/10.3350/cmh.2024.0465

View: 1510 Download: 73 Web of Science: 1 Crossref: 1

Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”

Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):705-708. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0372

View: 1953 Download: 65 Web of Science: 3 Crossref: 3

Core protein inhibitors: Opportunities and challenges at the forefront of hepatitis B cure: Editorial on “Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients”

Hae Lim Lee, Jeong Won Jang

Clin Mol Hepatol. 2024;30(4):692-694. Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0346

View: 1394 Download: 53

Original Article

Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction

Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim

Clin Mol Hepatol. 2024;30(3):539-560. Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0060 Correction in: Clin Mol Hepatol 2024;30(4):1060

View: 3610 Download: 267 Web of Science: 6 Crossref: 3

Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study

Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon

Clin Mol Hepatol. 2024;30(3):500-514. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0055

View: 3200 Download: 179 Web of Science: 2 Crossref: 3

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients

Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery

Clin Mol Hepatol. 2024;30(3):375-387. Published online March 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0535

View: 3547 Download: 124 Web of Science: 1 Crossref: 1

Review

Safety considerations for withdrawal of nucleos(t)ide analogues in patients with chronic hepatitis B: First, do no harm

Yao-Chun Hsu, Cheng-Hao Tseng, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(4):869-890. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2022.0420

View: 4601 Download: 225 Web of Science: 12 Crossref: 15

Original Article

Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma

Jeayeon Park, Sung Won Chung, Yun Bin Lee, Hyunjae Shin, Moon Haeng Hur, Heejin Cho, Min Kyung Park, Jeonghwan Youk, Ji Yun Lee, Jeong-Ok Lee, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Tae Min Kim, Jeong-Hoon Lee

Clin Mol Hepatol. 2023;29(3):794-809. Published online May 17, 2023

DOI: https://doi.org/10.3350/cmh.2023.0057

View: 4597 Download: 170 Web of Science: 2 Crossref: 1

Letter to the Editor

Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”

Chia-Ming Chu, Yun-Fan Liaw

Clin Mol Hepatol. 2023;29(2):510-512. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0018

View: 3345 Download: 77 Web of Science: 1 Crossref: 1

Original Article

Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase

Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(2):482-495. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0322

View: 4790 Download: 216 Web of Science: 16 Crossref: 19

Editorial

The imitator of immune-tolerant chronic hepatitis B: A killer in disguise

Moon Haeng Hur, Jeong-Hoon Lee

Clin Mol Hepatol. 2023;29(2):363-366. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0079

View: 3710 Download: 103 Web of Science: 2 Crossref: 2

Review

Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives

Shang-Chin Huang, Chun-Jen Liu

Clin Mol Hepatol. 2023;29(2):320-331. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0422

View: 8023 Download: 467 Web of Science: 35 Crossref: 39

Editorial

New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?

Young-Suk Lim

Clin Mol Hepatol. 2023;29(1):118-119. Published online November 29, 2022

DOI: https://doi.org/10.3350/cmh.2022.0413

View: 4149 Download: 189 Web of Science: 5 Crossref: 3

Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers

Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2023;29(1):113-117. Published online October 31, 2022

DOI: https://doi.org/10.3350/cmh.2022.0333

View: 3903 Download: 117 Web of Science: 3 Crossref: 4

Original Article

Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus

Daxian Wu, Qunfang Rao, Zhongyang Xie, Xiaoqing Zhu, Yuanmei Che, Jian Wu, Hainv Gao, Jingyu Zhang, Zhouhua Hou, Xiaoyu Cheng, Zeyu Sun

Clin Mol Hepatol. 2022;28(4):912-925. Published online July 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0121

View: 5458 Download: 155 Web of Science: 1 Crossref: 1

Review

RNA interference as a novel treatment strategy for chronic hepatitis B infection

Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2022;28(3):408-424. Published online February 17, 2022

DOI: https://doi.org/10.3350/cmh.2022.0012

View: 10527 Download: 682 Web of Science: 51 Crossref: 56

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

Sun Woong Kim, Jun Sik Yoon, Minjong Lee, Yuri Cho

Clin Mol Hepatol. 2022;28(1):17-30. Published online July 20, 2021

DOI: https://doi.org/10.3350/cmh.2021.0093

View: 12045 Download: 663 Web of Science: 43 Crossref: 41

Snapshot

History and future of hepatitis B virus control in South Korea

Do Young Kim

Clin Mol Hepatol. 2021;27(4):620-622. Published online September 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0277 Correction in: Clin Mol Hepatol 2022;28(4):939

View: 8756 Download: 165 Web of Science: 15 Crossref: 14

Original Article

Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea

Kyeong Deok Kim, Ji Eun Lee, Jong Man Kim, Okjoo Lee, Na Young Hwang, Jinsoo Rhu, Gyu-Seong Choi, Kyunga Kim, Jae-Won Joh

Clin Mol Hepatol. 2021;27(4):603-615. Published online September 8, 2021

DOI: https://doi.org/10.3350/cmh.2021.0137

View: 6083 Download: 147 Web of Science: 5 Crossref: 4

Review

Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma

Jer-Wei Wu, Jia-Horng Kao, Tai-Chung Tseng

Clin Mol Hepatol. 2021;27(4):524-534. Published online February 23, 2021

DOI: https://doi.org/10.3350/cmh.2021.0012

View: 14497 Download: 374 Web of Science: 24 Crossref: 26

1 | 2 | 3 | 4 |

Viewed By 6952	MAFLD: How is it different from NAFLD?
Viewed By 6180	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5291	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5142	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4657	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 298	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 266	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 170	MAFLD: How is it different from NAFLD?
Cited By 92	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 88	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search